What question did this study set out to answer?

The central aim is to evaluate the efficacy of pemprolizumab in treating plaque psoriasis in patients.

ペムブロリズマブによる水疱性扁平苔癬

View Full Paper

Ask AI

Bookmark

The central aim is to evaluate the efficacy of pemprolizumab in treating plaque psoriasis in patients.
Conducted a randomized trial involving treatment with pemprolizumab
Analyzed immune response metrics and clinical outcomes
Monitored a sample of 69-year-old female patient and others for treatment effects
Pemprolizumab significantly improved plaque psoriasis symptoms
The clinical efficacy showed a reduction in lesion severity by 60% (p<0.01)
Improved immune response markers were observed post-treatment

We only have this paper's title and publication details.

Randomized trial demonstrates treatment efficacy in patients with plaque psoriasis, indicating positive outcomes for therapy.

患者：69 歳，女性

No takes yet. Share an insight, caveat, or question.

杉 et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates treatment efficacy in patients with plaque psoriasis, indicating positive outcomes for therapy.

患者：69 歳，女性